Basic Information
| LncRNA/CircRNA Name | DLX6-AS1 |
| Synonyms | DLX6-AS1, DLX6-AS, DLX6AS, Evf-2, NCRNA00212 |
| Region | GRCh38_7:96955141-97014065 |
| Ensemble | ENSG00000231764 |
| Refseq | NR_015448 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | glioma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, Luciferase reporter assay, RIP, RNAi, other |
| Sample | glioma tissues and cell lines (U251, U87MG, T98G, SHG44) |
| Expression Pattern | up-regulated |
| Function Description | In the cellular functional assays, silenced DLX6-AS1 expression by siRNAs inhibited the proliferation, invasion and tumor growth in vitro and in vivo, while the enhanced DLX6-AS1 expression by plasmids promotes them. The bioinformatics predictive tools, luciferase reporter assay and correlation analysis found that miR-197-5p could both target the 3'-UTR of DLX6-AS1 as well as E2F1 gene, constructing DLX6-AS1-miR-197-5p-E2F1 axis. Moreover, receiver operating characteristic (ROC) curve analysis revealed that lncRNA DLX6-AS1 has valuable diagnostic value clinical diagnose for the glioma patients (AUC = 0.736). |
| Pubmed ID | 30366080 |
| Year | 2019 |
| Title | Long Noncoding RNA DLX6-AS1 Accelerates the Glioma Carcinogenesis by Competing Endogenous Sponging miR-197-5p to Relieve E2F1 |
External Links
| Links for DLX6-AS1 | GenBank HGNC NONCODE |
| Links for glioma | OMIM COSMIC |